医学
肝移植
移植
语句(逻辑)
协商一致会议
重症监护医学
器官移植
移植手术
内科学
肝病学
法学
政治学
作者
Marina Berenguer,Eléonora De Martin,Amelia J. Hessheimer,Josh Levitsky,Daniel G. Maluf,Valeria R. Mas,Nazia Selzner,Helena Hernàndez-Èvole,Alina Lutu,Nabeel Wahid,Haseeb Zubair
标识
DOI:10.3389/ti.2023.11358
摘要
Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.
科研通智能强力驱动
Strongly Powered by AbleSci AI